Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors

Authors

Keywords

Journal

Volume 32, Issue 8, Pages 817-825

Publisher

Ovid Technologies (Wolters Kluwer Health)

Online

2009-09-15

DOI

10.1097/cji.0b013e3181ad4d5d

Discuss science. Find collaborators. Network.

Join a conversation

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now